Fingerprint
Dive into the research topics of 'Phase I study of the mutant IDH1 inhibitor ivosidenib: Safety and clinical activity in patients with advanced chondrosarcoma'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
Phase I study of the mutant IDH1 inhibitor ivosidenib: Safety and clinical activity in patients with advanced chondrosarcoma
William D. Tap, Victor M. Villalobos, Gregory M. Cote, Howard Burris, Filip Janku, Olivier Mir, Murali Beeram, Andrew J. Wagner, Liewen Jiang, Bin Wu, Sung Choe, Katharine Yen, Camelia Gliser, Bin Fan, Sam Agresta, Shuchi S. Pandya, Jonathan C. Trent
Research output: Contribution to journal › Article › peer-review
77
Scopus
citations